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Clinical Investigations

The role of cardiac testing with the 0/1-hour
high-sensitivity cardiac troponin algorithm
evaluating for acute myocardial infarction
James McCord, MD a , Aeman Hana, MD b , Bernard Cook, PhD c , Michael P Hudson, MD a , Joseph Miller, MD d ,
Gray Akoegbe, MD e,1 , Christian Mueller, MD f , Michele Moyer, BS d , Gordon Jacobsen, PhD e,1 , and
Richard Nowak, MD d Detroit, MI; Atlanta, GA; Basel, Switzerland

Background

The role of cardiac testing in the 3 zones (rule-out, observation, and rule-in) of the 0/1-hour algorithm to
evaluate for acute myocardial infarction (AMI) has not been well studied. This study evaluated the 0/1-hour algorithm with
a high-sensitivity cardiac troponin (hs-cTnI) assay and investigated cardiac testing in the 3 zones.

Methods

Patients (n = 552) at a single urban center were enrolled if they were evaluated for AMI. Blood samples were
obtained at presentation, 1 hour, and 3 hours for hs-cTnI. Follow-up at 30 to 45 days for death/AMI was done. The results
of echocardiograms, stress testing, and coronary angiography were recorded.

Results

In total, 45 (8.2%) had AMI (27 Type 1 and 18 Type 2) during the index hospitalization while at follow-up
death/AMI occurred in 11 (2.0%) of patients. The rule-out algorithm had a negative predictive value for AMI of 99.6% while
the rule-in zone had a positive predictive value of 56.6%. The MACE rate at follow-up was 0.4% for those in the rule-out
group. There were 6/95 (6.3%) abnormal stress tests in the rule-out zone and 4 of these were false positives.

Conclusions

The 0/1-hour algorithm had high diagnostic sensitivity and negative predictive value for AMI, and adverse
events were very low in patients in the rule-out zone. Noninvasive testing in rule-out zone patients had low diagnostic yield.
(Am Heart J 2021;233:68–77.)

There are approximately 8 to 10 million people evaluated annually in emergency departments (EDs) in the
United States for possible acute myocardial infarction
(AMI).1 However, of these individuals 85% are ultimately
not diagnosed with an AMI.2-4 Much time and effort
are spent evaluating these individuals with electrocardiograms (ECGs), cardiac markers, and noninvasive cardiac
testing such as stress testing or coronary computed tomography angiography (CCTA). The annual cost of these
evaluations in the United States is estimated at $5 to 10
billion.5 Prolonged stays in the ED of these patients can
lead to overcrowding, which has been associated with
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worse clinical outcomes.6 , 7 Guidelines from the United
States recommend that cardiac troponin (cTn) be measured over 3 to 6 hours in the evaluation of possible
AMI.8 However, studies done mostly out of the United
States using high sensitivity cTn (hs-cTn) suggest that
AMI can be excluded at presentation or over 1 hour utilizing accelerated diagnostic protocols.
Multiple studies have shown that AMI can be excluded
at presentation when hs-cTn values are below the level
of detection with a negative predictive value (NPV) of
99.1% to 100%.9-12 In addition, there are studies demonstrating that a 0/1-hour algorithm looking at absolute
changes in hs-cTn to exclude AMI has a similar high
NPV.13-15 The 0/1-hour algorithm divides patients into
rule-out, observation, and rule-in zones. Both of these
strategies utilize values that are substantially below the
recommended 99th percentile cutoff value that is used
in the definition of AMI.16 The use of the 0/1-hour algorithm for the evaluation of possible AMI is recommended
by the European Society of Cardiology.17 , 18 Most of these
studies, however, only included patients with chest pain
and have excluded patients with significant renal insufficiency.13
The purpose of this study involving the 0/1-hour algorithm was 3-fold: first, validate a 0/1-hour algorithm with
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Figure 1

AMI, acute myocardial infarction; hs-cTnI, high sensitivity cardiac troponin I.

an hs-cTnI assay in a US cohort that has only been studied
in one European trial up to this point19 ; second, explore
the diagnostic utility of cardiac testing (echocardiogram,
stress testing and coronary angiography) in the 3 zones
of the algorithm; third, evaluate Type 1 and Type 2 AMIs
in the context of the 3 zones of the algorithm.

Methods
This was a substudy of the Rapid Evaluation of ACuTe
Myocardial InfarctiON in the US (REACTION-US) trial.
Details of the study have previously been published.20
Briefly this was a prospective observational study that
evaluated ED patients who had symptoms suspicious
for an AMI. Inclusion criteria required patients age 21
years of age or older with an ECG and at least 1 cTnI
ordered by the responsible clinician. Exclusion criteria
were acute issues requiring immediate lifesaving interventions, cardioversion, or defibrillation within the previous 24 hours, ST-segment elevation MI leading to immediate reperfusion therapy, women who were pregnant
or breast feeding, or patients that were transferred from
other facilities. Patients provided informed written consent, and the study was approved by the Institutional Review Board at Henry Ford Hospital, Detroit, Michigan.
Research coordinators enrolled the patients, obtained a
history from the patient, recorded the primary symptom at presentation, and reviewed the electronic medical
record.
Baseline blood samples were collected in ethylenediamine tetraacetic acid tubes within 60 minutes of the
completion of the presentation ECG in the ED. Additional
samples were collected at 1 hour and 3 hours. The tubes
of blood were centrifuged to obtain plasma and placed in
a −80°C freezer within 1 hour of sampling. Samples were

analyzed using the hs-cTnI Access assay (Beckman Coulter, Brea, CA) at Henry Ford Hospital. This hs-cTnI has
a 99th percentile of 18.2 ng/L, a limit of blank of 0.077
ng/L, a limit of detection of 0.32 ng/L, and limit of quantification of 0.77 ng/L.21 The 0/1-hour AMI algorithm that
places patients in a rule-out, observation, or rule-in zone
was evaluated. Patients in the rule-out zone had hs-cTnI
<4 ng/L at 0 hour or <5 ng/L at 0 hour and a delta from 0
to 1 hour <4 ng/L. Patients in the rule-in zone had 0 hour
≥50 ng/L or delta at 1 hour ≥15 ng/L. Patients that did
not meet the criteria for either the rule-in zone or ruleout zone were placed in the observation zone (Figure 1).
The hs-cTnI values for the algorithm were determined in
a prior study.19

0/1-hour algorithm with hs-cTnI
The determination of the final diagnosis of AMI was
done using the hs-cTnT (Roche Diagnostics, Indianapolis, IN) and required at least 1 hs-cTnT >19 ng/L, which
is the Food and Drug Administration approved 99th percentile for use in the United States.22 There were 3 physicians involved in the determination of AMI: 2 boardcertified cardiologists and 1 emergency physician. Two
physicians reviewed the cases independently and classified the AMI as either Type 1 or Type 2. Only in the case
of disagreement in the diagnosis of AMI (Type 1 or Type
2) between the initial 2 physicians was the case reviewed
by the third physician for final adjudication. The reviewing physicians also classified all deaths at follow-up as either cardiac or noncardiac and interpreted all ECGs. The
reviewing physicians had access to the electronic medical records, which included all testing done during the
admission. The determination of AMI was done in accordance with the principles of the universal definition of
MI.16 The results of both the hs-cTnI and the hs-cTnT
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were blinded to the responsible clinicians managing patients. At the time of this study neither hs-cTn assays
were approved for use in the United States. The assay
that was used clinically was the contemporary cTnI Ultra
(Siemens Medical Solutions, Malvern, PA). The 99th percentile of the Siemens assay is 40 ng/L and any number
above this was reported to the clinician.
Research personnel recorded the results of echocardiograms, stress tests, and coronary angiograms done during
the study. The ordering of cardiac tests was left to the discretion of the responsible clinician. An echocardiogram
was considered abnormal if there was any wall motion
abnormality noted (focal or global). Reports of the stress
tests were reviewed to classify the tests as positive, negative, or indeterminate. A coronary angiogram was considered abnormal if any blood vessel had a stenosis ≥70%
or a left main stenosis ≥50%. Research personnel contacted the enrolled patients at 30 to 45 days and 12 to 18
months after discharge to determine if they experienced
death, AMI, or a revascularization procedure (percutaneous coronary intervention [PCI] or coronary artery
bypass grafting surgery [CABG]). Follow-up information
was obtained from a telephone call and subsequent medical record review. If subjects or family members were not
able to be reached by telephone, an electronic medical
record review was completed. Also Ancestry.com Michigan obituaries was queried, and a Google search was
used. Beckman Coulter financially supported the study.
The authors are solely responsible for the design and conduct of the study, all study analyses, the drafting/editing
of the paper, and its final contents.

Statistical analysis
The baseline patient characteristics have been compared across the 3 algorithm zones using analysis of variance for numerical data, the chi-square test for nonsparse
categorical data, and the Fisher exact test for sparse categorical data. Cardiac procedure status has been compared across the 3 algorithm zones using the chi-square
test for nonsparse data and the Fisher exact test for
sparse data. Resulting P values less than .05 have been
considered statistically significant. All analyses have been
performed using SAS version 9.4 (SAS Institute, Inc.,
Cary, NC).

Results
Diagnostic/prognostic utility
From May 2013 to April 2015, there were 569 patients
that qualified as eligible patients. There were missing hscTnI data in 17 patients leading to 552 patients in the
final analysis. Baseline clinical characteristics, symptoms,
vital signs, ECG findings, and home medications of patients in the rule-out, observation, and rule-in zones are
shown (Table I). In general, patients in the rule-in zone,
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as compared to the rule-out zone, were older and had
more comorbidities, such as hypertension, hypercholesterolemia, prior AMI, or coronary revascularization procedures. The final diagnosis during the initial ED/hospital
presentation was AMI in 45 (8.2%) patients. In AMI patients that presented <3 hours after symptom onset
(n = 15) the median hs-cTnI value at time 0 was 25.1 ng/L
(interquartile range [IQR] 15.4-65.1 ng/L), as compared
to the AMI patients that presented later (n = 30) median hs-cTnI 78.9 ng/L (IQR 24.1-458.0 ng/L; P= .037).
Of the AMIs there was 1 ST-segment elevation MI (included as the patient was not recognized as such and did
not receive immediate reperfusion therapy) and the rest
were non-ST-segment MIs. There was good agreement between the 2 physicians determining AMI (kappa = 0.97;
95% confidence interval [CI] 0.92-1.00). In only 2 cases
of AMI was there disagreement requiring a third physician to adjudicate the case. Within 30 to 45 days, there
were 5 deaths (3 cardiac and 2 noncardiac), an additional
8 AMIs, and 23 revascularization procedures (20 PCIs and
3 CABGs).
Of the 270 patients in the rule-out category, there was
only 1 AMI yielding a NPV of 99.6% (95% CI 98.0-100)
and sensitivity of 97.8% (95% CI 88.2-99.9; Figure 2).
The median time from presentation to baseline blood
draw was 1 hour (IQR 0.8-1.1 hours), and the median
time for presentation to the 1-hour blood draw was 2.0
hours (IQR 1.8-2.2 hours). The one AMI patient that was
not identified by the rule-out algorithm was a 57-year-old
male with typical symptoms of increasing chest pressure
that was worsened by physical exertion. The patient reported continual symptoms for >24 hours prior to presentation. He underwent a PCI 1 month prior and had
diffuse coronary artery disease (CAD). He was placed in
the observation unit, and his cardiologist recommended
to discharge the patient with an increase in his antianginal medications. He did not suffer death or recurrent
AMI at 30 to 45 days. Of patients in the rule-out zone, 232
(85.9%) had an hs-cTnI <4 ng/L at presentation, while 38
(14.1%) required the 1-hour draw to rule-out. Of those in
the rule-in group, there were 30/53 (56.6 %) that had an
AMI yielding a positive predictive value (PPV) of 56.6%
(95% CI 42.3-70.2) and specificity of 95.5% (95% CI 93.397.1). Of patients in the observation zone, there were 14
(6.1 %) with AMI (Figure 2). Of patients with hs-cTnI ≥50
ng/L at presentation, 23 (53.5%) had an AMI; of patients
with a 1-hour increase of hs-cTnI ≥15 ng/L, 18 (81.8%)
had an AMI (P = .025). In looking at MACE by the 3
zones (rule-out, observation, rule-in): the 30- to 45-day
death/AMI rates by were 0.4%, 2.6%, and 7.5% (P= .003)
and the 12- to 18-month all-cause mortality rates were
0.7%, 4.8%, and 7.5% (P= .005; Figure 2), respectively.
The mortality rates and AMIs are cumulative over the 12to 18-month period. The median follow-up time was 12.2
months (IQR 12.1-12.4 months).
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Table I. Baseline clinical characteristics by the 3 zones

Demographics
Age, mean ± SD, years
Male gender (%)
Race, frequency (%)
Caucasian
African American
Other
History, frequency (%)
Hypertension
Diabetes
Hypercholesterolemia
Smoking
CAD
Family history of CAD
PCI
CABG
Prior acute myocardial infarction
Congestive heart failure
Dialysis
Presenting vital signs, mean ± SD
Systolic BP, mm Hg
Diastolic BP, mm Hg
Pulse rate, beats/min
Electrocardiogram ﬁnding, (%)
Atrial ﬁbrillation
Left ventricular hypertrophy
Left bundle branch block
Paced ventricular rhythm
ST-segment elevation ≥1 mm
ST-segment depression ≥1 mm
T-wave inversion
Within normal limits
Creatinine levels
Median IQR
Home medications, frequency (%)
Aspirin
Anticoagulant
Diuretics
Angiotensin-converting enzyme inhibitor
Angiotensin-receptor blocker
Beta-blocker
Calcium channel blocker
Nitrates

All patients (N = 552)

Rule-out (N = 270)

Observation (N = 229)

Rule-in (N = 53)

P value

55.6 ± 11.1
286 (51.8)

53.0 ± 10.4
106 (39.3)

57.9 ± 11.2
145 (63.3)

59.2 ± 10.5
35 (66.0)

<.001
<.001

90 (16.3)
459 (83.2)
3 (0.5)

55 (20.4)
214 (79.3)
1 (0.4)

23 (10.0)
204 (89.1)
2 (0.9)

12 (22.6)
41 (77.4)
0 (0.0)

.007

448 (81.2)
161 (29.2)
273 (49.5)
205 (37.1)
199 (36.1)
213 (38.6)
125 (22.6)
30 (5.4)
163 (29.5)
132 (23.9)
27 (4.9)

191 (70.7)
71 (26.3)
108 (40.0)
107 (39.6)
74 (27.4)
88 (32.6)
45 (16.7)
7 (2.6)
58 (21.5)
30 (11.1)
1 (0.4)

209 (91.3)
75 (32.8)
133 (58.1)
76 (33.2)
95 (41.5)
94 (41.0)
57 (24.9)
16 (7.0)
80 (34.9)
78 (34.1)
22 (9.6)

48 (90.6)
15 (28.3)
32 (60.4)
22 (41.5)
30 (56.6)
31 (58.5)
23 (43.4)
7 (13.2)
25 (47.2)
24 (45.3)
4 (7.5)

<.001
.284
<.001
.262
<.001
<.001
<.001
.003
<.001
<.001
<.001

144.5 ± 25.7
85.3 ± 17.4
83.6 ± 18.7

141.8 ± 22.1
84.5 ± 15.1
82.3 ± 17.5

147.2 ± 27.3
85.9 ± 18.8
84.2 ± 18.5

147.0 ± 33.3
87.3 ± 22.1
88.4 ± 24.5

.049
.452
.078

19 (3.4)
92 (16.7)
9 (1.6)
13 (2.4)
19 (3.4)
23 (4.2)
167 (30.3)
148 (26.8)

2 (0.7)
24 (8.9)
0 (0.0)
1 (0.4)
10 (3.7)
3 (1.1)
40 (14.8)
114 (42.2)

14 (6.1)
58 (25.3)
8 (3.5)
8 (3.5)
7 (3.1)
13 (5.7)
98 (42.8)
29 (12.7)

3 (5.7)
10 (18.9)
1 (1.9)
4 (7.5)
2 (3.8)
7 (13.2)
29 (54.7)
5 (9.4)

.003
<.001
.003
.002
.916
<.001
<.001
<.001

0.97(0.80-1.27)

0.86(0.75-1.01)

1.13(0.9-1.48)

1.11(0.88-1.57)

<.001

292 (52.9)
48 (8.7)
137 (24.8)
212 (38.4)
37 (6.7)
248 (44.9)
137 (24.8)
127 (23.0)

118 (43.7)
14 (5.2)
54 (20.0)
84 (31.1)
13 (4.8)
78 (28.9)
50 (18.5)
42 (15.6)

133 (58.1)
30 (13.1)
63 (27.5)
102 (44.5)
20 (8.7)
134 (58.5)
71 (31.0)
65 (28.4)

41 (77.4)
4 (7.5)
20 (37.7)
26 (49.1)
4 (7.5)
36 (67.9)
16 (30.2)
20 (37.7)

<.001
.007
.011
.002
0.211
<.001
.004
<.001

BP, blood pressure; CABG, coronar y arter y bypass graft; CAD, coronar y arter y disease; COPD, chronic obstructive pulmonar y disease; PCI, percutaneous coronary
intervention.

Stress testing, echocardiography, and coronary
angiography
Those in the rule-in zone more commonly had a wall
motion abnormality on their echocardiogram, an abnormal stress test with imaging, or required a revascularization procedure. Of patients in the rule-out zone, 95
(35.2%) received some form of stress testing, 22 (8.1%)
had an echocardiogram, and 9 (3.3%) underwent coronary angiography (Tables II and III). For patients in the
rule-out zone, the majority of stress tests 86 (90.5%) were
normal and these patients were discharged. There were
only 6 (6.3%) patients that were positive for ischemia
and 3 (3.2%) patients that were nondiagnostic (no fur-

ther testing done). Of the 6 patients with positive stress
tests, 2 of them underwent CCTAs and 2 underwent coronary angiography with all 4 demonstrating normal coronary arteries. Only 1 of these patients had a mildly positive stress nuclear test finding, which prompted a cardiology consult. This patient had a recent coronary angiogram and medical management was recommended.
There was 1 other patient that had an abnormal stress nuclear test and underwent coronary angiography, which
demonstrated significant left main disease which led to a
CABG surgery. This patient was a 65-year-old female with
a history of diabetes mellitus type 2 and hypertension
who presented with atypical chest pain.
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Figure 2

Patient outcomes in the rule-out, observation, and rule-in zones. AMI, acute myocardial infarction; MACE, major adverse cardiac event; MI,
myocardial infarction; NPV, negative predictive value; PPV, positive predictive value.

Characteristics of the 9 patients that had coronary angiography in the rule-out group are shown (Table III). Of
these there were 5 patients (all with a known history of
CABG or prior PCI) that went directly to coronary angiography based on the history without a stress test: 3
underwent PCI and with 2 medical therapy was advised.
There were also 2 patients that underwent coronary angiography after a normal stress due to clinical suspicion:
1 was normal and 1 had obstructive CAD but was treated
medically. All of the 4 revascularization procedures happened at the time of the index visit. Of the 22 patients in
the rule-out group that had an echocardiogram, 1 demonstrated a wall motion abnormality. The echocardiogram
demonstrated global hypokinesis with an ejection fraction of 40%, which was thought to be secondary to uncontrolled hypertension. Those in the rule-in group more
commonly had a revascularization procedure. The median length of stay of patients in the rule-out zone that
were discharged from the ED without stress testing or
echocardiography was 5.7 hours (IQR 4.7-7.0 hours),
which was significantly lower than those that had either

a stress test or echocardiogram 26.6 hours (IQR 21.1-31.1
hours; P< .001).

Types 1 and 2 AMIs and patient characteristics
There was a total of 27 Type 1 AMIs and 18 Type 2
AMIs (Figure 2). Patients with Type 1 AMIs more commonly had a history of PCI 18 (66.7%) when compared
to those with Type 2 AMIs 4 (22%) (P= .004). There was
no significant difference with other variables. There was
a significantly higher percentage of Type 2 AMIs in the
observation zone 9 (64.3%) when compared to the rulein zone 9 (30.0%) (P= .031). All 27 Type 1 AMIs had
chest pain as their primary presenting symptom while
14 (77.8%) of Type 2 AMIs had chest pain as the primary
symptom. Patients with Type 1 AMI had higher median
maximal hs-cTnI values over 3 hours of 214.6 ng/L (IQR
56.2-746.7) when compared to Type 2 AMIs at 73.4 ng/L
(IQR 44.2-182.5), but this was not a significant difference (P= .102). Similarly, patients with Type 1 AMIs had
a greater change from presentation to 1 hour 15.4 ng/L
(IQR 2.6-54.4 ng/L) as compared to Type 2 AMIs at 10.6
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.003
.200
<.001
.008
.326
0
0
2 (67)
4 (40)
0
14 (45)
0
1 (33)
2 (20)
20 (80)
17 (55)
0
0
4 (40)
5 (20)
31
0
3
10
25
0
0
3 (21)
4 (7)
0
14 (22)
1 (100)
1 (7)
5 (9)
9 (82)
<.001
(8)
(5)
(56)
(2.2)

CABG, coronary artery bypass grafting; DSE, dobutamine stress echocardiogram; PCI, percutaneous coronary intervention.

49 (78)
0
10 (71)
45 (83)
2 (18)
63
1
14
54
11
14 (26.4)
0
0
0
3 (5)
0
(5)

1
0
3
3
5
5
21 (95)
4 (100)
33 (92)
49 (89)
4 (44)
22
4
36
55
9
4 (1.5)
Echocardiogram
Exercise stress test
Exercise echocardiogram or nuclear stress test
Pharmacological nuclear stress test or DSE
Coronary angiogram
PCI or CABG

Normal Abnormal Nondiagnostic
Normal Abnormal Nondiagnostic N

Observation zone (n = 229) N (%)

Normal Abnormal Nondiagnostic N

Rule-out zone (n = 270) N (%)

Table II. Cardiac testing in the rule-out, observation, and rule-in zones

N

Rule-in zone (n = 53) N (%)

P value

McCord et al 73

ng/L (IQR 3.8-20.7 ng/L), but this was not significant (P=
.749).
Although chest pain was the primary symptom in 41
(91.1%) of the AMI patients, the other 4 (8.9%) had a
primary symptom of dyspnea or palpitations. In AMI
patients, the median time from symptom onset to presentation was 10.2 hours (IQR 1.9-50.2 hours). There
were 14 (31.1%) AMI patients that presented within 2
hours after symptom onset and 7 (15.6%) that presented
within 1 hour of symptom onset. There were 27 patients
with end-stage renal disease (ESRD) requiring dialysis, of
which 4 had an AMI (2 in the observation zone and 2 in
the rule-in zone). Only 1 of these 27 patients was in the
rule-out zone. The PPV/specificity (56.6%/95.5%) for the
rule-in zone was not significantly different if the dialysis
patients were excluded from the analysis, 57.1%/95.7%
(P= 1.000/.280).
For study patients 105 (19%) were not able to be contacted by telephone for follow-up at 30 to 45 days. Of
these patients all had review of their electronic medical record. Of the patients that were not contacted by
telephone, there was 1 cardiac death confirmed by a
hospital admission. Of these 105 patients there were 77
(73%) that had no Henry Ford Hospital visits documented
within the 30 to 45 days. However, at later follow-up of
12 to 18 months, there were only 14 (18%) of the 77 that
did not have some documentation of an encounter in
the medical record. Thus, ultimately there were 14/552
(2.5%) lost to direct follow-up. None of these 14 patients
were found in a query of Ancestry.com Michigan obituaries.

Discussion
To the best of our knowledge, this is the first study
that has evaluated the diagnostic utility of noninvasive
cardiac testing (echocardiography and stress testing) and
described Type 1 and Type 2 AMIs in the context of the
0/1-hour AMI evaluation algorithm using a newer hs-cTnI
assay in the ED. We report 3 key findings.
First, using a new hs-cTnI assay in a 0/1-hour algorithm
demonstrated high diagnostic and prognostic utility. To
date, there has only been 1 other publication to evaluate this particular hs-cTnI using the 0/1-hour algorithm.19
The actual numbers used in these algorithms are assay
specific and will depend on the specific manufacturer of
the hs-cTn assay. The 0/1-hour algorithm had high NPV
(99.6%) and sensitivity (97.8%) for AMI. These results
are similar to other hs-cTn assays that have been studied
in the 0/1-hour algorithm (sensitivities of 97.1%-97.6%
and NPVs of 98.9%-99.2%).13 , 14 , 23 In our study, there was
only 1 AMI missed with the 0/1-hour algorithm. This patient was recognized based on the history alone as high
risk and diagnosed with unstable angina. The 0/1-hour
algorithm should not be used alone and should always
be used in conjunction with the history and ECG. Those
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Table III. Patients receiving a coronary angiogram in the rule-out zone
Patient age
and gender
50 male
61 female

60 male
55 male

57 male
49 female
65 female
40 female
76 female

Medical history

Symptoms

No cardiac history or
risk factors
Acute myocardial
infarction with prior
PCI/DES to LAD
CAD with prior PCI/DES
to LAD
CAD with prior
PCI/stent to RCA and
circumﬂex
Uncontrolled
Hypertension
Hypertension, smoker,
family history of CAD
Hypertension, diabetes
mellitus type 2
CAD known single
vessel disease
CABG

Stress test

Echocardiogram

Coronary angiogram Revascularization

Typical angina No

No

Nonobstructive CAD

No

Typical angina No

No

Severe in-stent
restenosis of LAD

PCI/DES to LAD

Typical angina No

No

Single-vessel CAD

PCI/DES to LAD

Typical angina No

No

Patent stent to RCA
and circumﬂex

No

Atypical chest
pain
Atypical chest
pain
Atypical chest
pain
Typical angina

Positive

No

Nonobstructive CAD

No

Positive

No

Normal coronaries

No

Positive

No

CABG

Negative

No

95% distal left main
stenosis
Single-vessel CAD

Typical angina Dobutamine stress
echocardiogram
cancelled due to
severe pulmonary
hypertension

PCI/DES to RCA

Severe pulmonary Occluded left internal No
hypertension
mammar y arter y
and saphenous
vein graft, 100%
stenosis LAD ﬁlled
by collaterals

CAD, coronary artery disease; CABG, coronary artery bypass grafting; DES, drug eluting stent; LAD, left anterior descanting artery; PCI, percutaneous coronary intervention;
RCA, right coronary artery.

in the rule-out zone had an excellent prognosis. At 30
to 45 days, there were neither cardiac deaths nor additional AMIs. There was 1 noncardiac death. At 12 to 18
months, there was 1 additional death, which was cardiac.
It should be noted the PPV for AMI for those in the rulein zone was modest at 56.6%. However, we did demonstrate that an increase of hs-cTnI ≥15 ng/L at 1 hour was
significantly more predictive of an AMI as compared to
the single threshold of 50 ng/L at presentation.
Second, the majority of patients (145 [53.7%]) in the
rule-out zone were recognized as low risk and sent home
without further testing with a good 30 to 45 day prognosis. No cardiac deaths or subsequent AMI occurred
in between hospital presentation and 30 to 45 days in
any rule-out group patient. However, 126 (46.7%) went
on to have an echocardiogram, stress test, or coronary
angiography. There were 95 patients that underwent a
stress test, of which 89 (93.7%) did not demonstrate ischemia. Of the 6 patients with an abnormal stress test, 4
were determined to be a false positive by either CCTA or
coronary angiography. There was 1 patient with known
CAD that had a mildly positive stress test where medical
therapy was advised. There was 1 patient with a positive
stress test that led to coronary angiography where severe left main disease was identified, which led to CABG.
There were 5 patients (4 with history of CAD) that went
to coronary angiography based on their history; 4 patients did not have stress testing and 1 had a negative

stress test. Thus, in the entire group in the rule-out zone,
a stress test significantly altered management in only 1
patient. In addition, only 1 of the patients in the rule-out
zone had a wall motion abnormality on an echocardiogram.
The diagnostic utility of stress testing in low-risk patients as defined by the 0/1-hour algorithm is likely very
limited. A large international study involving over 22,000
patients from 15 cohorts demonstrated that that those
with very low hs-cTnI or hs-cTnT at presentation and
very little change at 45 minutes to 2 hours were at
very low risk for 30-day death or AMI.24 Studies have
shown there is an association between hs-cTnT values
and coronary artery atherosclerotic burden by CCTA in
stable outpatients. Those with normal CCTAs had very
low hs-cTnT levels, while those with higher risk features,
such as multivessel disease or remodeled plaques, had
the highest values.25 , 26 These findings suggest that stress
testing might not be helpful in those with very low hscTn values. However, it should be noted stress testing
was not investigated in these studies. Studies of low-risk
patients being evaluated for possible AMI have shown
the false-positive rate of different stress testing modalities ranged from 67% to 100%.27 , 28 Most patients in the
0/1-hour rule-out zone likely can be discharged. Based on
clinical judgment, there may be a minority that need further testing, such as stress testing, in those with known
CAD, or CCTA in those without known CAD. However,
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even if it is decided that patients need further testing,
this likely can be done outpatient. There has been concern with the introduction of hs-cTn that there would be
an increase in unnecessary stress testing and coronary
angiography. A study of 2544 patients showed that the
rate of coronary angiography was similar before and after the introduction of hs-cTn, as was the percentage of
coronary angiographies that showed no obstructive disease. However, the use of stress testing was significantly
lowered from 29% to 19% as was the time to discharge.29
Greater than 40% of patients in our study in the rule-out
zone were held for cardiac testing that added >20 hours
to their length of stay. Thus, it is possible many in the
rule-out zone do not need an extended stay for further
cardiac testing and could be sent home for an out-patient
evaluation. To prove this the algorithm would need to be
prospectively implemented.
Third, there was a higher proportion of Type 2 AMIs
in the observation zone 9 (64.3%) when compared to
the rule-in zone 9 (30.0%). Type 2 AMIs had lower levels of hs-cTnI and also had a smaller change in hs-cTnI
over 1 hour, although these differences were not statistically significant. Lower levels of cTn and less of a change
over time in Type 2 AMIs has been reported in other
studies.30 , 31 These findings could be important in clinical cases when there is uncertainty about the type of
AMI, which could impact the specific treatment plan and
the disposition of the patient. Patients with Type 1 AMIs
would likely best be managed on a cardiology service
while the best disposition of Type 2 AMIs would depend
on the underlying primary problem, such as sepsis or pulmonary embolism. We also noted that those with Type
1 AMIs more commonly had chest pressure or crushing
chest pain as their primary symptom while those with
Type 2 AMIs more frequently had dyspnea or dizziness,
which has been noted in prior studies.32
Finally, we demonstrated the 0/1-hour algorithm to be
an effective diagnostic tool in the manner it would be
practically implemented in the ED. Prior studies of the
0/1-hour algorithm only included individuals that had
chest discomfort as their presenting symptom.13-15 However, atypical presentations of AMI exist, and many individuals are evaluated for possible AMI in EDs with symptoms other than chest discomfort such as dyspnea, syncope, or palpitations. There are reports that up to 33%
of AMI patients do not have chest discomfort.24 Patients
were included in our study if there was some clinical suspicion for AMI irrespective of presenting symptoms. In
the AMI group, 4 (8.9%) did not have chest discomfort
as the presenting symptom. Also, there has been concern that the 0/1-hour algorithm may not perform as
well in patients that present early after symptom onset
as many studies did not include a large number of such
patients. The European Society of Cardiology guidelines
suggest the 0/1-hour algorithm not be used in patients
that present <3 hours after symptom onset.28 In our
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study, 14 (31.1%) of the AMI patients presented <2 hours
after symptom onset and 7 (15.6%) presented within 1
hour of symptom onset. Although these numbers are
modest, it is reassuring that the 0/1-hour algorithm performed well in these patients.
We included ESRD patients in the study and there was
no difference in the specificity or PPV of the rule-in zone
protocol with the inclusion of these patients. Although
the number of ESRD patients was small, this suggests
the algorithm could be used in such patients, but very
few patients with ESRD would fulfill the rule-out protocol and require later hs-cTn measurements. A prior study
evaluated a 0/1-hour algorithm in patients with renal dysfunction but not requiring dialysis.33 This study found
that using different cut-points for the rule-in did not significantly improve the diagnostic utility of the algorithm
and recommended using the established algorithm. Since
safety is the most important consideration in the use of
the algorithm, it seems simpler and reasonable to apply
the standard algorithm in those with ESRD with the realization that only a few will reside in the rule-out zone.
Finally, over 80% of the patients were African American
which distinguishes this analysis from other studies of
the 0/1-hour algorithm where this population has been
underrepresented.

Limitations
This was a single-center trial in a US urban setting
with a modest number of patients at 552. If this were
a multicenter trial involving different communities and
more patients, the results may have been different. The
hs-cTnI assay used was applied retrospectively and was
not known to the responsible clinicians. The algorithm
should be prospectively validated with this assay. Of the
AMI patients, only 7 (15.6%) presented within 1 hour of
symptom onset. If there were a larger percentage of early
presenters, the NPV may not have been as favorable. The
number of AMIs was modest at 45. Finally, there were 14
(2.5%) we were not able to obtain any follow-up information at 12 to 18 months.

Conclusion
We demonstrated that in a largely African American
population evaluated for AMI in the ED the 0/1-hour algorithm using a hs-cTnI assay had high sensitivity for AMI
and identified a population at low risk for death/AMI at
30 to 45 days. Noninvasive testing with echocardiography or stress testing had low diagnostic yield in patients
in the rule-out zone. Patients in the rule-out zone could
be considered for outpatient evaluation, which would
significantly decrease the length of stay in the ED. Finally
Type 2 AMIs more commonly were found in the observation as compared to the rule-in zone.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on February 10, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

76 McCord et al

Conﬂict of interest
The authors had total control of the data for independent analyses, interpretation, and writing. Dr. McCord has received research funding from Abbott Diagnostics, Roche Diagnostics, Beckman Coulter, and
Siemens Healthineers; and has been a consultant to
Roche Diagnostics, Siemens Healthineers, and Beckman
Coulter. Dr. Cook has received research funding from
Beckman Coulter, Roche Diagnostics, Critical Diagnostics, and Greiner Bio-One; and has been a consultant
to Beckman Coulter and Roche Diagnostics. Dr. Miller
has received research funding from Beckman Coulter,
NeuMoDx, Gilead, Calcimedica, and BrainScope. Dr.
Mueller has received research support from the Swiss
National Science Foundation, the Swiss Heart Foundation, the Kommission fur Technologie und Innovation,
the Stiftung fur Kardiovaskulare Forschung Basel, the
University of Basel, Abbott, AztraZeneca, Beckman Coulter, Biomerieux, Brahms, Ortho Clinical Diagnostics,
Roche, Siemens, Singulex, Sphingotec, and the University Hospital Basel; and has received speaker honoraria
and/or consulting honoraria from Abbott, Amgen, AstraZeneca, Biomerieux, Boehringer Ingelheim, BristolMyers Squibb, Brahms, Cardiorentis, Novartis, Roche,
Sanofi, Siemens, and Singulex. Dr. Nowak has been a
consultant for Siemens Healthineers, Roche Diagnostics,
Beckman Coulter, Ortho Diagnostics, and Abbott Diagnostics. All other authors have reported that they have
no relationships relevant to the contents of this paper to
disclose.

Funding
The study was funded by Beckman Coulter.

References
1. Owens PL, Barrett ML, Gibson TB, et al. Emergency department
care in the United States: a proﬁle of national data sources. Ann
Emerg Med 2010;56:150–65.
2. Pollack Jr CV, Sites FD, Shofer FS, et al. Application of the TIMI
risk score for unstable angina and non-ST elevation acute
coronary syndrome to an unselected emergency department chest
pain population. Acad Emerg Med 2006;13:13–18.
3. Chase M, Robey JL, Zogby KE, et al. Prospective validation of the
thrombolysis in myocardial infarction risk score in the emergency
department chest pain population. Ann Emerg Med
2006;48:252–9.
4. Hollander JE. The continuing search to identify the very-low-risk
chest pain patient. Acad Emerg Med 1999;6:979–81.
5. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke
statistics–2014 update: a report from the American Heart
Association. Circulation 2014;129 e28-e292.
6. Guttmann A, Schull MJ, Vermeulen MJ, Stukel TA. Association
between waiting times and short term mortality and hospital
admission after departure from emergency department:
population based cohort study from Ontario, Canada. BMJ
2011;342:d2983.

American Heart Journal
Month 2021

7. Diercks DB, Roe MT, Chen AY, et al. Prolonged emergency
department stays of non-ST-segment-elevation myocardial
infarction patients are associated with worse adherence to the
American College of Cardiology/American Heart Association
guidelines for management and increased adverse events. Ann
Emerg Med 2007;50:489–96.
8. Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC
Guideline for the Management of Patients with non-ST-elevation
acute coronary syndromes: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol 2014;64 e139-e228.
9. McRae AD, Innes G, Graham M, et al. Undetectable
concentrations of a food and drug administration-approved
high-sensitivity cardiac troponin T assay to rule out acute
myocardial infarction at emergency department arrival. Acad
Emerg Med 2017;24:1267–77.
10. Shah AS, Anand A, Sandoval Y, et al. High-sensitivity cardiac
troponin I at presentation in patients with suspected acute
coronary syndrome: a cohort study. Lancet 2015;386:2481–8.
11. Pickering JW, Young JM, George PM, et al. Validity of a novel
point-of-care troponin assay for single-test rule-out of acute
myocardial infarction. JAMA Cardiol 2018;3:1108–12.
12. Sandoval Y, Smith SW, Shah AS, et al. Rapid rule-out of acute
myocardial injury using a single high-sensitivity cardiac troponin I
measurement. Clin Chem 2017;63:369–76.
13. Mueller C, Giannitsis E, Christ M, et al. Multicenter evaluation of
a 0-hour/1-hour algorithm in the diagnosis of myocardial
infarction with high-sensitivity cardiac troponin T. Ann Emerg Med
2016;68:76–87 e4.
14. Jaeger C, Wildi K, Twerenbold R, et al. One-hour rule-in and
rule-out of acute myocardial infarction using high-sensitivity
cardiac troponin I. Am Heart J 2016;171:92–102 e1-5.
15. Neumann JT, Sorensen NA, Schwemer T, et al. Diagnosis of
myocardial infarction using a high-sensitivity troponin I 1-hour
algorithm. JAMA Cardiol 2016;1:397–404.
16. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal deﬁnition
of myocardial infarction (2018). Circulation 2018;138
e618-e651.
17. Stepinska J, Lettino M, Ahrens I, et al. Diagnosis and risk
stratiﬁcation of chest pain patients in the emergency department:
focus on acute coronary syndromes. A position paper of the
Acute Cardiovascular Care Association. Eur Heart J Acute
Cardiovasc Care 2020;9:76–89.
18. Rofﬁ M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the
management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation: Task Force for the
management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation of the European Society of
Cardiology (ESC). Eur Heart J 2016;37:267–315.
19. Boeddinghaus J, Nestelberger T, Twerenbold R, et al.
High-sensitivity cardiac troponin I assay for early diagnosis of
acute myocardial infarction. Clin Chem 2019;65:893–904.
20. Nowak RM, Gandolfo CM, Jacobsen G, et al. Ultrarapid rule-out
for acute myocardial infarction using the generation 5 cardiac
troponin T assay: results from the REACTION-US study. Ann
Emerg Med 2018;72:654–64.
21. Christenson RH, Duh SH, Mullins KE, et al. Analytical and clinical
characterization of a novel high-sensitivity cardiac troponin assay
in a United States population. Clin Biochem 2020;83:28–36.
22. US Food and Drug Administration. US Department of Health and
Human Services. 510(k) premarket notiﬁcation: K162895.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on February 10, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

American Heart Journal
Volume 233

23.

24.

25.

26.

27.

Elecsys Troponin T Gen 5 STAT Assay. Elecsys Troponin T Gen 5
STAT CalSet, Elecsys PreciControl Troponin, Elecsys Troponin T
Gen 5 CalCheck 5; 2017.
Rubini Gimenez M, Twerenbold R, Jaeger C, et al. One-hour
rule-in and rule-out of acute myocardial infarction using
high-sensitivity cardiac troponin I. Am J Med 2015;128:861–70
e4.
Neumann JT, Twerenbold R, Ojeda F, et al. Application of
high-sensitivity troponin in suspected myocardial infarction. N
Engl J Med 2019;380:2529–40.
Korosoglou G, Lehrke S, Mueller D, et al. Determinants of
troponin release in patients with stable coronary artery disease:
insights from CT angiography characteristics of atherosclerotic
plaque. Heart 2011;97:823–31.
Laufer EM, Mingels AM, Winkens MH, et al. The extent of
coronary atherosclerosis is associated with increasing circulating
levels of high sensitive cardiac troponin T. Arterioscler Thromb
Vasc Biol 2010;30:1269–75.
Hartsell S, Dorais J, Preston R, et al. False-positive rates of
provocative cardiac testing in chest pain patients admitted to an
emergency department observation unit. Crit Pathw Cardiol
2014;13:104–8.

McCord et al 77

28. Michaels A, Gibbs J, Mawri S, et al. Prognostic utility of the
HEART score in the observation unit. Crit Pathw Cardiol
2018;17:179–83.
29. Twerenbold R, Jaeger C, Rubini Gimenez M, et al. Impact of
high-sensitivity cardiac troponin on use of coronary angiography,
cardiac stress testing, and time to discharge in suspected acute
myocardial infarction. Eur Heart J 2016;37:3324–32.
30. Greenslade JH, Adikari T, Mueller C, et al. Characteristics and
occurrence of type 2 myocardial infarction in emergency
department patients: a prospective study. Emerg Med J
2018;35:169–75.
31. Nestelberger T, Boeddinghaus J, Badertscher P, et al. Effect of
deﬁnition on incidence and prognosis of type 2 myocardial
infarction. J Am Coll Cardiol 2017;70:1558–68.
32. Lippi G, Sanchis-Gomar F, Cervellin G. Chest pain, dyspnea and
other symptoms in patients with type 1 and 2 myocardial
infarction. A literature review. Int J Cardiol 2016;215:20–2.
33. Twerenbold R, Badertscher P, Boeddinghaus J, et al. 0/1-Hour
triage algorithm for myocardial infarction in patients with renal
dysfunction. Circulation 2018;137:436–51.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on February 10, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

